[Dynamic of indicators of ambulatory care of tuberculosis in the antituberculous center of Adjamé]. / Dynamique des indicateurs de la prise en charge ambulatoire de la tuberculose au centre antituberculeux d'Adjamé.

INTRODUCTION: Tuberculosis (TB) remains a real problem of public health in Côte d'Ivoire. The aim of our study is to describe the dynamic of anti-TB fight indicators in anti-TB center (CAT) of Adjamé. METHODOLOGY: We realized a retrospective study, comparing the anti-TB activities of two periods (1999-2001 versus 2010-2012) at the CAT of Adjamé. Over two periods, 24,520 cases of TB were recorded in the registers of TB declaration. RESULTS: Logistic regression results were the following ones. The proportion of the patients of Adjamé municipality increased to detriment of the patients coming from other municipalities. Our study showed an increase of TB contagious forms, a reduction of new cases of TB. The rate of screening of HIV infection increased. We noted a reduction of TB-HIV co-infection prevalence. The proportion of smear positive at the 2nd month decreased. We noted an increase of the rate therapeutic success and a reduction of lost at follow-up. CONCLUSION: Important progresses were realized in the TB fight and TB-HIV co-infection.

[Influence of care pathways on the time of initiation of TB treatment]. / Influence du parcours de soins sur le délai d'initiation du traitement antituberculeux.

INTRODUCTION: Untreated positive pulmonary TB smear has both individual implications, increasing morbidity and mortality, and collective implications, increasing the contagiousness of the disease. The present study aims to identify the course of patient care and the influence of care pathway on the time of initiation of TB treatment in Abidjan. METHODS: We conducted a prospective and comparative study between two groups with pulmonary smear-positive: 38 with a conventional course (use of only the health facilities) and 198 with mixed driving (combining health facilities, self-medication and traditional medicine). RESULTS: The average time between onset of symptoms and initiation of treatment for patients with conventional path was significantly different from that observed in patients with mixed course (4.28 weeks versus 8.57 weeks, P < 0.001). Multivariate analysis mixed route was related to level of education (OR=2.728 [1.165-6.386]; P=0.02), the district of residence (OR=2.690 [1.168-6.195]; P=0.02), the mode of onset of symptoms (OR=0.33 [0.101-0.6607]; P=0.013) and weight loss (OR=0.259 [0.139-0.798]; P=0.004). CONCLUSIONS: The course of patients are multiple and can induce delays in starting treatment for tuberculosis. The sensitization of the population and the involvement of traditional healers in TB screening may contribute to the early therapeutic management.

[Antituberculous retreatement in case of failure to category I regimen]. / Le retraitement antituberculeux en cas d'échec au régime de catégorie I.

INTRODUCTION: In Côte d'Ivoire, since April 2002, the antituberculous regime for category I patients (ARC-I) passed from 2RHZ/4RH to 2RHZE/4RH, without modification of the antituberculous regime for category II (ARC-II) for treatment of cases of the failures to respond to treatment with ARC-I (FARC-I) and patients with a relapse of tuberculosis (TR). The objective of this study was to determine the outcome of patients treated by ARC-II (2RHZES/1RHZE/5RHE). METHODOLOGY: This study was retrospective and compared outcomes during patient follow-up under ARC-II between 1999-2000 (period 1=267 cases) and 2004-2005 (period 2=434 cases). The ARC-II regime has been prescribed for 297 cases of FARC-I and 404 cases of TR. RESULTS: The failure rate of the ARC-II regime was estimated to be 11.98% during the first period compared to 5.53% during the second (P<0.001). Among FARC-I cases, therapeutic failure was estimated to 20.54% versus 5.92% in TR group (P<0,001). We noted a positive sputum smear among FARC-I : 16.16% at the second month, 13.13% to the third month and 20.54% at the fifth month versus 4.20% at the second month, 1.48% to the third month and 5.92% at the fifth month within TB cases (P<0.001). CONCLUSION: Management of failures to the ARC-I regime must be reviewed to prevent the development of multidrug resistant TB.